Jiangsu Trautec Medical Technology Co., Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2015

Location

Changzhou Jiangsu China

Primary Industry

Biotechnology

About

Founded in 2015 and based in Changzhou, China, Jiangsu Trautec Medical Technology Co., Ltd. operates as a biomedical developer that focuses on recombinant collagen based biomaterials R&D. The company has R & D base and production plant located in Changzhou, Xining and Changsha. The company cooperates with Chinese University of Hong Kong, Shanghai Changhai Hospital, Shenzhen Bay laboratory Pingshan Center to laboratory and research institute. Jiangxia is the CTO of the company, and the total cost of the project he presided over exceeded HKD 10 million. Haihang Li is the CIO of the company and he participated in the national key research and development plan of the ministry of science and technology - stem cell and transformation research. The company provides recombinant human-derived collagen products. The business of the company includes the development and production of recombinant collagen-based biomaterials. The company's products include recombinant type I collagen, recombinant type III collagen and recombinant type XVII collagen.

Current Investors

Boyu Capital, Holley Group Co., Ltd, CDH Baifu Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biotechnology, Pharmaceutical Research & Development

Website

www.trautec.com.cn/

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.